STADA Arzneimittel (ETR:SAZ) received a €74.40 ($88.57) price target from analysts at Nord/LB in a note issued to investors on Tuesday. The brokerage currently has a “sell” rating on the stock. Nord/LB’s price objective points to a potential downside of 15.60% from the stock’s current price.
A number of other research analysts also recently commented on the stock. Commerzbank set a €66.25 ($78.87) target price on shares of STADA Arzneimittel and gave the company a “sell” rating in a research report on Wednesday, December 20th. Independent Research set a €89.00 ($105.95) target price on shares of STADA Arzneimittel and gave the company a “neutral” rating in a research report on Wednesday, December 20th. Warburg Research set a €74.40 ($88.57) target price on shares of STADA Arzneimittel and gave the company a “sell” rating in a research report on Wednesday, December 20th. Finally, S&P Global set a €74.40 ($88.57) price objective on shares of STADA Arzneimittel and gave the stock a “sell” rating in a research report on Friday, November 10th. Four analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The company presently has a consensus rating of “Sell” and a consensus price target of €74.08 ($88.18).
STADA Arzneimittel (ETR SAZ) opened at €88.15 ($104.94) on Tuesday. The company has a market cap of $5,490.00 and a price-to-earnings ratio of 57.99. STADA Arzneimittel has a 52-week low of €46.31 ($55.13) and a 52-week high of €89.21 ($106.20).
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
What are top analysts saying about STADA Arzneimittel? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for STADA Arzneimittel and related companies.